JPWO2022197755A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022197755A5 JPWO2022197755A5 JP2023557351A JP2023557351A JPWO2022197755A5 JP WO2022197755 A5 JPWO2022197755 A5 JP WO2022197755A5 JP 2023557351 A JP2023557351 A JP 2023557351A JP 2023557351 A JP2023557351 A JP 2023557351A JP WO2022197755 A5 JPWO2022197755 A5 JP WO2022197755A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently selected
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 35
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 239000001301 oxygen Substances 0.000 claims 18
- 229910052717 sulfur Chemical group 0.000 claims 18
- 239000011593 sulfur Chemical group 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 11
- 125000001931 aliphatic group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- -1 imidazopyridinediyl Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162494P | 2021-03-17 | 2021-03-17 | |
| US63/162,494 | 2021-03-17 | ||
| PCT/US2022/020474 WO2022197755A1 (en) | 2021-03-17 | 2022-03-16 | Imidazopyridinyl inhibitors of plasma kallikrein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510502A JP2024510502A (ja) | 2024-03-07 |
| JP2024510502A5 JP2024510502A5 (https=) | 2025-03-21 |
| JPWO2022197755A5 true JPWO2022197755A5 (https=) | 2025-03-21 |
Family
ID=81325446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557351A Pending JP2024510502A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレインのイミダゾピリジニル阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4308227A1 (https=) |
| JP (1) | JP2024510502A (https=) |
| CN (1) | CN117396473A (https=) |
| WO (1) | WO2022197755A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| US20050192314A1 (en) * | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| MX2011012037A (es) * | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
| EP2627178B1 (en) * | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| JP6665154B2 (ja) * | 2014-07-17 | 2020-03-13 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換尿素誘導体及びその薬学的使用 |
| KR20200143376A (ko) * | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| BR112023018619A2 (pt) * | 2021-03-17 | 2023-11-28 | Takeda Pharmaceuticals Co | Inibidores de heteroaril de calicreína plasmática |
| US20240382482A1 (en) * | 2021-03-17 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors |
-
2022
- 2022-03-16 CN CN202280033913.6A patent/CN117396473A/zh active Pending
- 2022-03-16 WO PCT/US2022/020474 patent/WO2022197755A1/en not_active Ceased
- 2022-03-16 EP EP22714692.5A patent/EP4308227A1/en active Pending
- 2022-03-16 JP JP2023557351A patent/JP2024510502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2007528417A5 (https=) | ||
| US20100041708A1 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| JPWO2019236890A5 (https=) | ||
| JPWO2019183367A5 (https=) | ||
| HUE034869T2 (en) | Combination therapy with substituted oxazolidinones | |
| JP2009526761A5 (https=) | ||
| JPWO2021107065A5 (https=) | ||
| JPWO2022197755A5 (https=) | ||
| JPWO2022197758A5 (https=) | ||
| CN115515603A (zh) | 用于治疗戊型肝炎的双环和单环核苷类似物 | |
| JPS63215625A (ja) | 抗健忘薬 | |
| JP2021521179A5 (https=) | ||
| JPWO2022197763A5 (https=) | ||
| JPWO2022197756A5 (https=) | ||
| WO2014092514A1 (ko) | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2024522142A (ja) | 高血圧の治療又は予防のためのピリダジノン | |
| JP5994059B2 (ja) | 抗マラリア活性を有するアザアルテミシニン誘導体及びその製造方法 | |
| JPWO2023060057A5 (https=) | ||
| JP3049284B2 (ja) | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 | |
| RU2008115937A (ru) | Новые амино-алкиламидные производные в качестве лигандов ccr3 рецептора | |
| JPS5821634B2 (ja) | シンキイミダゾ （１，２−ａ）ｓ− トリアジンルイノセイゾウホウホウ | |
| ES2368334T3 (es) | Compuesto de n-fenilarilsulfonamida, composición farmacéutica que comprende el compuesto como principio activo, intermedio sintético para el compuesto y procedimientos para su preparación. | |
| RU2025100893A (ru) | Замещенные производные гетероциклических соединений и их фармацевтическое применение |